Cell Biotech Co

Cell Biotech Co FCF Yield

The Free Cash Flow Yield of Cell Biotech Co (049960.KQ) as of Nov 19, 2026 is 8.40 %. In the previous year, Free Cash Flow Yield was 19.11 % — a change of -56.06% (lower).

FCF Yield

8.40 %

YoY

-56.06%

Last updated:

Free Cash Flow Yield of Cell Biotech Co is 2025 8.40 % . Free Cash Flow Yield of Cell Biotech Co was 2024 19.11 % . It decreases by -56.06% lower compared to the previous year.

The Cell Biotech Co FCF Yield history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

FCF Yield
Date
FCF Yield
Jan 1, 2018
7.30 KRW
Jan 1, 2019
0.81 KRW
Jan 1, 2020
6.89 KRW
Jan 1, 2021
14.92 KRW
Jan 1, 2022
10.78 KRW
Jan 1, 2023
6.51 KRW
Jan 1, 2024
19.11 KRW
Jan 1, 2025
8.40 KRW
The Cell Biotech Co FCF Yield history
YEARFCF YieldYoY
8.40 %-56.06%
19.11 %+193.45%
6.51 %-39.56%
10.78 %-27.79%
14.92 %+116.55%
6.89 %+749.73%
0.81 %-88.89%
7.30 %-60.01%
18.25 %+8.45%
16.83 %+6.62%
15.78 %+74.26%
9.06 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Cell Biotech Co Stock analysis

What does Cell Biotech Co do? Cell Biotech Co., Ltd. generates revenue through the production and sale of probiotic lactobacillus products. The company manufactures lactic acid bacteria (LAB) powders, which serve as raw materials for foods and medicines targeting immunization enhancement and digestion improvement. Finished products containing LABs are sold for intestinal health improvement, carcinogen inhibition, and calcium supplementation, distributed domestically and internationally. The firm focuses on functional health applications within the probiotics market. The company's primary customers are domestic and international food and pharmaceutical manufacturers seeking functional ingredients, as well as end consumers purchasing finished probiotic products. LAB powders are supplied to food and medicine producers, while finished products reach consumers directly for health benefits. Distribution channels include both local and global markets, emphasizing the functional health segments of the industry. Cell Biotech's product portfolio centers on LAB-based solutions for health enhancement, with no additional brands or external partnerships mentioned in the business description. The company operates solely within the probiotics sector, leveraging its research and development capabilities to create products aligned with digestive and immune health needs. Cell Biotech Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Cell Biotech Co stock

Free Cash Flow Yield of Cell Biotech Co is 8.40 % in 2025.

Free Cash Flow Yield of Cell Biotech Co changed from 19.11 % to 8.40 %, representing a -56.06% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Free Cash Flow Yield Cell Biotech Co since 2006 – with annual values, charts, and detailed analysis.

FCF Yield measures the free cash flow per share relative to the stock price. It indicates how much cash a company generates for each dollar invested.

To evaluate Free Cash Flow Yield's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Free Cash Flow Yield.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Free Cash Flow Yield's Cell Biotech Co with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Valuation — Cell Biotech Co

All Key Metrics — Cell Biotech Co